This is a preview of subscription content, log in via an institution to check access.
Notes
containing a 20:1 ratio of cannabidiol to delta-9-tretrahydrocanabidiol, with an estimated concentration of 16.0−24.0 mg/mL
Reference
Elliott J, et al. Economic Evaluation of Cannabinoid Oil for Dravet Syndrome: A Cost-Utility Analysis. PharmacoEconomics : 14 May 2020. Available from: URL: https://doi.org/10.1007/s40273-020-00923-5
Rights and permissions
About this article
Cite this article
Cannabinoid oil cost-effective choice for Dravet syndrome in Canada. PharmacoEcon Outcomes News 854, 9 (2020). https://doi.org/10.1007/s40274-020-6839-9
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-020-6839-9